| War of words heats up over Thermo Fisher’s $1.3B bid for California firm Just this morning, Affymetrix said it’s postponing a shareholder vote scheduled for Thursday on whether to accept the $1.3 billion offer made by Waltham-based Thermo Fisher. Behind Bristol-Myers' $600M acquisition of an Atlas biotech startup Today’s acquisition is the first to be announced this year for a Massachusetts-based biotech firm. Newest cystic fibrosis drug by Vertex said to be too costly by U.K. agency Reuters reported today that the National Institute for Health and Care Excellence, or NICE, said the drug Orkambi, priced at an annual cost equivalent to $148,000 per patient, was not a cost-effective. Kendall Square to sprout location kiosks to tell people where they are Sarah Gallop, who was elected president of the Kendall Square Association this morning, plans a handful of “way-finding” kiosks to be built in key areas around the square. Lexington diagnostic company looks to cancer test with $46M raise | 
